Seventh Circuit to hear Lilly appeal over retatrutide's regulatory status

The U.S. Court of Appeals for the Seventh Circuit is scheduled to hear argument on September 24 in Eli Lilly and Company v. Robert F. Kennedy, Jr., a case that turns on how retatrutide — Lilly's experimental triple-action obesity medicine — is classified under federal law ^[1]. Lilly wants it treated as a biologic; the FDA says it is a conventional drug ^[1].

Retatrutide has not been approved by the FDA or any other regulator ^[2]. It targets three hormone receptors — GLP-1, GIP and glucagon — and in trials it delivered average weight loss of 28.3 percent at 80 weeks, a result the analysis describes as roughly matching the most effective bariatric operations ^[1][2]. Lilly has said it intends to file for approval in early 2027 ^[1][2]. Because the molecule is still in Phase 3 testing, the only legitimate routes to it today are Lilly-sponsored trials or, in limited cases, the FDA's expanded access framework; Frier Levitt notes there is no lawful retail, pharmacy or wellness channel for it ^[2].

Two amino acids, and a disputed calendar

At issue is a definition. The FDA calls a protein "any alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size," and biologics are not eligible for compounding ^[1]. Lilly counted a 39-amino-acid backbone plus a two-amino-acid side chain, reaching 41, and requested the biologic label ^[1]. In March 2024 the agency turned it down, reading "alpha" as applying to every amino acid in the definition ^[1].

Lilly sued that September, arguing the denial was arbitrary, capricious and contrary to the FDA's own rules ^[1]. In 2025, Judge Tanya Walton Pratt agreed the molecule misses the strict protein test but found the agency handled the separate "analogous to a protein" question capriciously, and sent the matter back ^[1].

Each side now reads the clock differently. Lilly contends the 60-day statutory window for classification restarted when the district court remanded the case, expired, and therefore triggers a provision that grants the designation the company asked for; the FDA maintains that deadline governs only the original request, not a decision a court has vacated ^[1]. The Outsourcing Facilities Association, which represents compounding facilities, filed in support of the agency and described the appeal as a "money grab," also arguing it is not properly before the court ^[1]. Lilly took its appeal to the Seventh Circuit on February 17, 2026 ^[1].

Why it matters for patients

The label carries money and access consequences. Biologic products get 12 years of statutory exclusivity, while new drugs get five, and their follow-on competitors face a tougher approval path ^[1]. Compounding exemptions do not reach biologics at all, so a Lilly win would foreclose compounded versions of retatrutide, while a loss would leave open a cheaper channel — although the FDA has said retatrutide "cannot be used in compounding under federal law," and Frier Levitt writes that no compounding exception covers an unapproved molecule still in trials ^[1][2]. If retatrutide is licensed as a biological product under Section 351 of the Public Health Service Act, the 503A and 503B compounding provisions would not provide a route to copies ^[2].

The price gap explains why the question draws so much attention. Compounded GLP-1s have been selling for roughly $150 to $200 a month, against self-pay prices of $299 to $449 for the top doses of brand-name versions ^[1]. Novo Nordisk's chief executive has put the number of Americans getting tirzepatide or semaglutide from compounders at 1.5 million, a figure the analysis says may understate reality ^[1]. On the other side, Deloitte has estimated $2.671 billion to develop and launch a new drug, and obesity trials are unusually long — at least two Phase 3 studies running more than a year each, with retatrutide's lasting 80 weeks apiece ^[1].

What happens next

Argument is set for September 24; no decision date has been reported ^[1]. Lilly's stated plan is still to submit retatrutide for FDA review in early 2027 ^[1][2]. In a separate enforcement push, the company filed six federal lawsuits on August 12, 2026, in four Texas district courts against four research-use-only sellers, a med spa and a compounding pharmacy, seeking permanent injunctions, disgorgement and attorney's fees ^[1][2]. Lilly says it has referred more than 200 people and businesses to regulators and flagged more than 14,000 websites, advertisements and social media listings offering retatrutide globally ^[2].